The Biocodex Microbiota Foundation is looking for young researchers to help understand the links between diet interactions with gut microbiome in gastrointestinal disorders
REDWOOD CITY, Calif., Oct. 12, 2017 /CNW/ -- The Biocodex Microbiota Foundation (BMF), an organization founded by Biocodex North America and dedicated to inspiring scientific projects that explore the structure of microbiota, is calling for research proposals from innovative Canadian researchers in the microbiome field.
The Canadian Biocodex Microbiota Foundation 2017 grant will be awarded to an investigator studying dietary interactions with the gut microbiome in gastrointestinal (GI) disorders, evaluating the mechanisms of these dietary interactions with microbes inhabiting the gut. Studies in translational animal models are encouraged. Young investigators are encouraged to apply.
Biocodex North America, a pharmaceutical company and maker of Florastor®, has been a leading researcher and provider in the microbiota field for the last 30 years. As the company continues to evolve, more emphasis has been placed on increasing awareness and placing reputable data at the fingertips of both consumers and healthcare professionals. To push this initiative forward, Biocodex launched in tandem the Biocodex Microbiota Foundation and the Biocodex Microbiota Institute in June of 2017. Together, these two entities are working to advance research and understanding of the human microbiota and gut flora.
The Foundation's annual call for projects is part of a multi-year research initiative to understand the interaction between microbiota and different pathologies. This year, by focusing on dietary interactions with the gut microbiome in GI disorders such as ulcerative colitis, Crohn's disease, irritable bowel syndrome (IBS), and celiac disease, the Canadian Biocodex Microbiota Foundation aims to understand the mechanisms behind common ailments affecting the Canadian population.
For example, studies show that IBS, a chronic and often debilitating functional gastrointestinal disorder, could affect as many as 13-20% of Canadians at any given time. The lifetime risk for a Canadian to develop IBS is 30%. And it is estimated that celiac disease, a genetic autoimmune condition, affects as many as 1 in every 100 - 200 people in North America. As many as 300,000 Canadians could have this disease; however, many remain undiagnosed.
The total grant amount is 25,000 euros, and the deadline to submit applications is 5 p.m. PT on November 3rd, 2017. The winner will be a selected by December 15, 2017, and notified no later than December 31, 2017.
Applicants must have an advanced degree, and young investigators are encouraged to apply. The grant must be applied to research in a Canadian institution. The applications will be reviewed and the winner chosen by BMF's scientific board, comprised of Dr. Levinus (Leo) Dieleman from University of Alberta and Dr. Elena Verdu from McMaster University.
About Biocodex North America Biocodex North America is a Silicon Valley-based pharmaceutical company dedicated to providing its customers with meaningful healthcare solutions with an emphasis on gastroenterology and oncology supportive care. Florastor® Daily Probiotic Supplements remain the flagship products, available at all major retailers nationwide. Biocodex North America is a subsidiary of Biocodex, a family-owned multinational pharmaceutical, research, development, manufacturing, and commercial enterprise operating in more than 100 countries. Visit http://www.biocodex.ca/en/for more information.
About Biocodex Microbiota Institute The Biocodex Microbiota Institute (BMI) offers the first major international platform to house data on human microbiota. Over recent years, growing interest has spawned a great deal of research into the role and importance of microbiota in maintaining good health. Given its background and expertise, Biocodex has chosen, through BMI, to lay the foundation for a vast network of scientifically rigorous data on microbiota, where patients and health professionals can learn about crucial advances in this field. With the discovery and worldwide marketing of the unique probiotic yeast strain, Saccharomyces boulardii lyo CNCM I-745, the company has, over 60 years, built a dual reputation as a pioneer and leader in the field of human microbiota.
BMI brings together all current knowledge and constantly collects new data on microbiota. It then shares the information regularly via communication tools and social media. As an important player in the health industry, Biocodex is proud to offer, through BMI, a source of information that meets the needs of all.
About Biocodex Microbiota Foundation The Biocodex Microbiota Foundation's mission is to support research into microbiota and its interaction with various pathologies. Research is supported through grants given to projects that investigate the implication of microbiota in human health. BMF supports both foundational and applied research. Projects are selected annually by a committee of independent, international scientists.
The BMF's primary activity remains the awarding of annual grants to innovative scientific research projects that explore the structure of microbiota and, in particular, the impact of an imbalance in microbiota, known as dysbiosis, on the occurrence or evolution of various pathologies.
The BMF also runs and helps establish programs to improve our understanding of microbiota and disseminates this knowledge as widely as possible by organizing scientific meetings dedicated to microbiota with pertinent training sessions. Finally, the BMF can establish public projects which aim to help improve human health and which involve microbiota.
The Biocodex Microbiota Foundation (BMF) is a non-profit, general interest organization.